|
General Account - Intramural Support
|
GenAcctIntraSupp12
|
$227,058
|
N/A
|
N/A
|
|
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm
|
5R44CA123994-06
|
$980,392
|
GILLESPIE, JOHN
|
20/20 GENESYSTEMS, INC.
|
|
Novel small-molecule TNF-a modulators as chemoprotective agents
|
5R44CA141749-03
|
$542,156
|
SHAW, JIAJIU
|
21ST CENTURY THERAPEUTICS, INC.
|
|
High Throughput 3D Cell Assay for Metastatic Prostate Cancer
|
1R41CA165463-01A1
|
$199,134
|
TAKAYAMA, SHUICHI
|
3D BIOMATRIX, INC.
|
|
Sustained, target delivery for treatment of cervical pathologies
|
1R43CA162417-01A1
|
$253,110
|
Spencer, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies
|
1R43CA162629-01A1
|
$193,879
|
Serrero, Ginette
|
A AND G PHARMACEUTICAL, INC.
|
|
Novel agent to restore sensitivity to anti-estrogen therapy
|
N43CO120060-000
|
$199,380
|
SERRERO, PH.D., GINETTE
|
A&G PHARMACEUTICAL, INC
|
|
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t
|
1R42CA171552-01
|
$472,301
|
Desai, Neil
|
AADI, LLC
|
|
AAG12006001
|
PUR2765678
|
$150,000
|
N/A
|
AAG12006001
|
|
Breast Cancer Oxaliplatin Microdosing Trial
|
N43CO120084-000
|
$199,969
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS
|
|
Phase 0 Carboplatin Microdosing Diagnostic Trial.
|
N44CO120048-000
|
$1,499,894
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS
|
|
Decreasing calories, fat and sodium in restaurant meals for widespread industry a
|
2R44CA150528-02A1
|
$497,642
|
HILL, ESTHER
|
ACCENTS ON HEALTH, INC.
|
|
ACO12051001
|
PUR2802756
|
$1,505,100
|
N/A
|
ACO12051001
|
|
Ultrasound Ablation on Bone Cancer Under CT Fluoroscopy
|
5R44CA112852-05
|
$941,541
|
Burdette, Everette
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
OTHER FUNCTIONS ADP SOFTWARE
|
N02CA120465-000
|
$14,970
|
NA, NA
|
ACTIGRAPH, LLC
|
|
Targeting B-cell lymphoma with Leukothera
|
1R41CA173900-01
|
$202,601
|
Belinka, Benjamin
|
ACTINOBAC BIOMED, INC.
|
|
Prevention of Tumor Recurrence Following Surgical Resection (Phase II)
|
6R44CA135967-03
|
$498,107
|
Wolinsky, Jesse
|
ACUITYBIO CORPORATION
|
|
Operation and Maintenance of the Biological Data Processing System
|
N02CM100009-004
|
$951,953
|
TEKLU, YOHANESS
|
ADDIS INC:1108540
|
|
IeDEA West -Africa collaboration
|
5U01AI069919-07
|
$308,922
|
Dabis, Francois
|
ADERA
|
|
Data acquisition system for multiplex analysis of color encoded particles
|
5R42CA140109-04
|
$682,533
|
Gorbovitski, Boris
|
ADVANCED BIOMEDICAL MACHINES, INC.
|
|
PFK-015: An inhibitor of PFKFB3 to treat Glioblastomas
|
1R43CA165300-01A1
|
$157,920
|
Tapolsky, Gilles
|
ADVANCED CANCER THERAPEUTICS, LLC
|
|
Automated Systems for Detection and Molecular Characterization of Circulating Tum
|
5R44CA122444-06
|
$979,021
|
LUO, YULING
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Detection of Light Chain Restriction in non-Hodgkin Lymphoma by a Novel RNA In Si
|
1R43CA168019-01
|
$268,010
|
Ma, Xiao-Jun
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-04
|
$1,917,582
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
|
1R43CA159797-01A1
|
$187,201
|
Triglia, Dennis
|
AGONOX, INC.
|
|
The 3D whole Body Distribution of NIR transferrin using FRET tomography imaging
|
5R21CA161782-02
|
$199,576
|
BARROSO, MARGARIDA
|
ALBANY MEDICAL COLLEGE
|
|
Regulation of Fibronectin Matrix Assembly by uPAR
|
5R01CA058626-19
|
$272,648
|
MC KEOWN-LONGO, PAULA
|
ALBANY MEDICAL COLLEGE
|
|
Concerted role for integrin alpha3beta1 and TGFb signaling in cancer progression
|
5F32CA153976-02
|
$53,942
|
Subbaram, Sita
|
ALBANY MEDICAL COLLEGE
|
|
Screening Assays for Small Molecules Targeting Oncogenic eIF4E Expression
|
1R01CA164006-01
|
$295,065
|
Yan, Chunhong
|
ALBANY MEDICAL COLLEGE
|
|
The Role of ATF3 in the DNA Damage Response
|
5R01CA139107-03
|
$254,412
|
Yan, Chunhong
|
ALBANY MEDICAL COLLEGE
|
|
Developing Rwandan Research Capacity in Cervical Cancer and other AIDS Malignanci
|
5D43CA153793-03
|
$473,439
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Central Africa IeDEA
|
5U01AI096299-02
|
$92,399
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Prospective Oral HPV and Risk of Head and Neck Cancers
|
5R21CA152785-02
|
$181,341
|
BURK, ROBERT
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Persistent HPV in Women at Risk for Cervix Cancer
|
5U01CA078527-15
|
$567,757
|
BURK, ROBERT
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
MOTILITY AND INVASION
|
5P01CA100324-10
|
$2,016,840
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Signal Transduction & Actin During Amoeboid Chemotaxis
|
5R01CA150344-24
|
$353,827
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
5U54CA163131-02
|
$784,552
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Diabetes Prevention Program Long-Term Follow-up Study
|
5U01DK048349-19
|
$25,274
|
CRANDALL, JILL
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Targeted therapy of pancreatic cancer with in vivo radionuclide generator
|
5R21CA156088-02
|
$216,630
|
DADACHOVA, EKATERINA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
PTEN and the molecular genetics of endometrial cancer
|
5R01CA097097-09
|
$314,583
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease
|
5R01CA128943-04
|
$334,117
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
DNA mismatch repair and cancer in murine models
|
5R01CA076329-15
|
$376,370
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Expanded Phase II Trial of Carraguard for Prevention of HPV Infection
|
5R01CA148966-03
|
$804,139
|
EINSTEIN, MARK
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
The role of macroH2A variants in cancer and senescence
|
1R01CA155232-01A1
|
$346,179
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S4
|
$3,757,417
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S5
|
$249,999
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S6
|
$249,999
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S7
|
$75,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-14
|
$513,291
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Center for AIDS Research (CFAR)
|
5P30AI051519-10
|
$248,678
|
GOLDSTEIN, HARRIS
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|